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Dr Paul W. M. Fedak (Calgary, Alberta, Canada). There is
clear clinical evidence that even with early and successful reperfu-
sion after coronary occlusion, patients will undergo progressive
cardiac remodeling that can lead to heart failure. The key molec-
ular and cellular changes that occur after reperfusion are not
well known. It gives us a window of opportunity where we could
potentially treat patients early during or after reperfusion to pre-
vent maladaptive signals from happening, but we need to under-
stand them better. Your work is important because it leads us inrdiovascular Surgery c Volume 145, Number 1 275
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ing with those molecular and cellular changes.
What is unique and important is that you have been able to sep-
arate out region- and time-specific changes in a preclinical relevant
animal model. What is really important is that you are able to sep-
arate ECM interstitial signaling from the cellular changes. It is dif-
ficult to present that complexity of data in such a short period of
time, and you did a great job. I have a couple of questions for you.
You have designed your experiment to look at mechanistic data
and tried to tease out time- and region-specific changes and corre-
late those events. I note with your data you are trying to correlate
MT1-MMP activity and LTB processing, but in the remote area
during reperfusion you observed the highest levels of the MMP ac-
tively, but you didn’t observe the similar changes in the LTB pro-
cessing. Does that refute your hypothesis?
Dr Eckhouse. I believe the differences seen in MT1-MMP and
LTBP-1 activity with microdialysis actually support our
hypothesis.
First, in examining MT1-MMP activity with microdialysis dur-
ing the I/R protocol, there are several possible reasons that could
lead to this increased MT1-MMP activity in the remote region.
Previous studies from other laboratories have determined that
a phosphorylation event occurring at the C-terminus of MT1-
MMP can lead to a substrate specificity and directed localization
within a cell membrane. From these findings, our research group
hypothesizes that post-translational modifications of MT1-MMP
in vivo are promoting increased cleavage of the MT1-MMP fluo-
rogenic peptide in a region-dependent manner.
An important question to consider is how are the MT1-MMP
and LTBP-1 substrates different? The peptide sequences of each
substrate are different. The MT1-MMP fluorogenic peptide is
a synthetic amino acid sequence that is hydrolyzed specifically
by MT1-MMP in vitro and in vivo. Previous validation studies
confirmed that the amino acid sequence is specific for MT1-
MMP over other MMPs. The LTBP-1 fluorogenic peptide repre-
sents an endogenous substrate sequence that is hydrolyzed by
MT1-MMP. Previous in vivo studies have determined that with
overexpression of MT1-MMP, there is a decrease in full-length
LTBP-1 and an increase in the low-molecular-weight split prod-
ucts of LTBP-1 after MT1-MMP–mediated hydrolysis. Therefore,
MT1-MMP differentially processes the 2 synthetic peptides.
The cleavage of the LTBP-1 fluorogenic peptide was specific to
the I/R region, which is supported by the increase in the activation
of the TGF-ß profibrotic pathway as measured by pSmad2 in the
I/R region when compared with the remote region. Although not
in the presentation, gene expression of collagen 1A1 by quantita-
tive PCR was increased, which further suggests increased acute
activation of the TGF-ß profibrotic pathway within the I/R region
that was not measured within the remote region, as demonstrated
by no change in collagen 1A1 gene expression and a small increase
in pSmad2 protein abundance when compared with the referent
control.
Dr Fedak. Can you speculate what the triggers could be here?
Could wall stress be the key trigger, and if so, can you think of any-
thing we can do from a surgical point of view early after
reperfusion?
Dr Eckhouse. Wall stress has been demonstrated to be an im-
portant mechanism in activating MT1-MMP. We have seen this276 The Journal of Thoracic and Cardiovascular Surgin a recent murine model of pressure overload hypertrophy from
our laboratory published by Dr Zile and in in vitro aortic wall stress
studies.
The alteration in stress–strain patterns due to an acute I/R event
is causing an increase in MT1-MMP activation. Therefore, de-
creasing wall stress due to I/R remains important.
For a future surgical technique, it will be important to improve
stress–strain patterns. Although this may be more relevant to
a chronic infarction, improving the thickness of the affected myo-
cardium within the I/R injury region by injections of polymers or
other method is currently under investigation. However, there is
a lot of area for creativity.
Dr Fedak. Thank you.
Dr Joseph D. Schmoker (Burlington, Vt). To follow up on
Paul’s question about regional issues, there is a mechanism for un-
coupling of TGF-ß via mechanical transduction through the integ-
rin network, I believe. I was wondering if you came across that
mechanism and if that could serve as an explanation for why
you are seeing this only in the region of I/R?
Dr Eckhouse. I haven’t come across that mechanism specifi-
cally within this study, but one of my predecessors in the labora-
tory, Dr Ruddy, looked at the TGF-ß pathway within in vitro
studies of aortic wall stress. We are currently investigating in-
creased TGF-ß activation secondary to increased aortic wall stress
in models of aortic aneurysms. However, I haven’t looked at that
within the I/R myocardial model, but that is definitely an area to
look at.
Dr Schmoker. My other question relates to miR-133a, which
has been used as a biomarker in clinical trials. Could it be that
the interstitial levels you are measuring are simply secondary to
cell injury or death secondary to reperfusion? Have you looked
at that? In other words, do you have histology on your I/R region?
DrEckhouse. I don’t have histology data to present.We did cell
culture studies using primary porcine fibroblasts undergoing sim-
ulated in vitro I/R, and what we found when we measured miR-
133a within the conditioned media is consistent with our in vivo
evidence. When it comes to cell death, previous studies using
that same I/R model did not show increased cardiomyocyte death,
and we didn’t have increased fibroblast cell death with our simu-
lated hypoxia reoxygenation model.
Concurrently, with potential cell death within the I/R region, I
would have expected miR-133a extracellularly to increase more
with apoptosis and cell death and spillage of the intracellular
miR-133a into the interstitial space. However, with I/R within
that I/R region, we actually see a decrease during the ischemic
time of miR-133a.
Dr Schmoker. Right, but I think it is in the reperfusion episode
where you are really going to get the cell injury or death.
One last point. Cardiac myocytes are enriched with miR-133a,
but I don’t know the relative abundance of that miR-133a in fibro-
blasts. So I am wondering why you didn’t use cardiomyocytes in
your cell culture.
Dr Eckhouse. That is a study we are currently doing. We ha-
ven’t completed that study.We have been able to show a correlation
between MT1-MMP levels and miR-133a in myocardial fibro-
blasts. So we are able to demonstrate that miR-133a is within other
cells besides the cardiomyocytes, but we are specifically looking at
the cardiomyocytes now.ery c January 2013
Eckhouse et al Evolving Technology/Basic ScienceDr Stephen McKellar (Rochester, Minn). Elegant study and
model. Good presentation. You presented your I/R model here,
but have you looked at this or similar phenomena in an infarction
modelwith sampling in the infarct, border zones, and then distantly?
This is an elegant way of studying that region. Is that something you
could at least speculate on what you might find in that model?
Dr Eckhouse. A previous study evaluated MT1-MMP activity
within an infarction model with a subsequent I/R event 2 weeks af-
ter the infarction. MT1-MMP activity increased with infarction
and then subsequently increased even more after a subsequent
I/R event 2 weeks later. However, in regard to miR-133a, we
haven’t looked at the long-term effects of I/R on miR-133a levels,
but it is definitely something we are interested in.
Dr Thomas K.Waddell (Toronto, Ontario, Canada). My ques-
tion is along the lines of Dr Schmoker’s question about the release
of miR-133. You mentioned that the exportation was identified as
a mechanism of regulation, but on the 2 slides you showed, it was
clear that the Yaxis was different. So when you measured by PCR
the levels of the miR-133 in the interstitium versus the total, what
was the scale of that difference? I would put it to you that if theThe Journal of Thoracic and Catotal is a million, then what you are measuring in the interstitium
is 10. It probably doesn’t reflect regulation. What I would like you
to think about is perhaps it is a mechanism of communication—the
exportation of miR-133 allows that to be diffused outward. If that
is the case, youmight actually see increasing penumbra of decreas-
ing miR-133 levels. So you may want to look at your remote area
a little bit as proximal and distant remote.
Dr Eckhouse.Wedidn’t look at proximal and distant remote re-
gions of the myocardium. That is an interesting point and defi-
nitely a suggestion we will take to the laboratory. Our data with
our miR exportation seem to fit nicely with our acute TGF-ß acti-
vation. In the remote region, we saw a decrease in the interstitial
miR-133a levels, and it remained decreased with reperfusion,
which in comparison with total myocardial pools leads us to be-
lieve that miR-133a remains elevated intracellularly. Thus, miR-
133a can inhibit or attenuate the TGF-ß profibrotic pathway within
the remote region. Within the I/R region, the extracellular increase
in miR-133a may be associated with a intracellular decrease of
miR-133a, which may then allow activation of the TGF-ß profi-
brotic signaling pathways and promote fibrosis over time.rdiovascular Surgery c Volume 145, Number 1 277
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